KORU Medical Systems to Participate in Upcoming Investor Conferences
KORU Medical Systems (NASDAQ: KRMD), a leading medical technology company, will participate in two upcoming investor conferences. The company focuses on developing, manufacturing, and commercializing innovative large volume subcutaneous infusion solutions. The management team will attend the 15th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 19th, 2024. Additionally, they will participate in the Canaccord MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 21st, 2024.
KORU Medical Systems (NASDAQ: KRMD), un'azienda leader nel settore della tecnologia medica, parteciperà a due prossime conferenze per investitori. L'azienda si concentra sullo sviluppo, la produzione e la commercializzazione di soluzioni innovative per l'infusione sottocutanea ad alto volume. Il team di gestione parteciperà al 15° Annuale Craig-Hallum Alpha Select Conference il martedì 19 novembre 2024. Inoltre, parteciperanno al Canaccord MedTech, Diagnostics and Digital Health & Services Forum giovedì 21 novembre 2024.
KORU Medical Systems (NASDAQ: KRMD), una empresa líder en tecnología médica, participará en dos próximas conferencias para inversores. La compañía se enfoca en el desarrollo, fabricación y comercialización de soluciones innovadoras para la infusión subcutánea de gran volumen. El equipo de gestión asistirá a la 15ª Conferencia Anual Craig-Hallum Alpha Select el martes 19 de noviembre de 2024. Adicionalmente, participarán en el Foro Canaccord MedTech, Diagnostics and Digital Health & Services el jueves 21 de noviembre de 2024.
KORU Medical Systems (NASDAQ: KRMD), 선도적인 의료 기술 회사가 두 개의 다가오는 투자자 회의에 참가할 예정입니다. 이 회사는 혁신적인 고용량 피하 주입 솔루션의 개발, 제조 및 상업화에 중점을 두고 있습니다. 경영진은 제15회 크레이그-할럼 알파 셀렉트 컨퍼런스에 참석할 예정이며, 2024년 11월 19일 화요일에 열립니다. 또한, 캐너코드 메드텍, 진단 및 디지털 건강 및 서비스 포럼에 2024년 11월 21일 목요일에 참석할 것입니다.
KORU Medical Systems (NASDAQ: KRMD), une entreprise leader dans le secteur des technologies médicales, participera à deux prochaines conférences pour investisseurs. L'entreprise se concentre sur le développement, la fabrication et la commercialisation de solutions innovantes d'infusion sous-cutanée à volume élevé. L'équipe de direction assistera à la 15ème Conférence Annuelle Craig-Hallum Alpha Select le mardi 19 novembre 2024. De plus, ils participeront au Forum Canaccord MedTech, Diagnostics and Digital Health & Services le jeudi 21 novembre 2024.
KORU Medical Systems (NASDAQ: KRMD), ein führendes Unternehmen im Bereich Medizintechnologie, wird an zwei bevorstehenden Investorenkonferenzen teilnehmen. Das Unternehmen konzentriert sich auf die Entwicklung, Herstellung und Vermarktung innovativer großvolumiger subkutaner Infusionslösungen. Das Management-Team wird am 15. Jahrestreffen der Craig-Hallum Alpha Select Conference am Dienstag, den 19. November 2024 teilnehmen. Außerdem werden sie am Canaccord MedTech, Diagnostics and Digital Health & Services Forum am Donnertag, den 21. November 2024 teilnehmen.
- None.
- None.
KORU Medical’s management team is participating at the 15th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 19th, 2024.
KORU Medical’s management team will also be participating at the Canaccord MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 21st, 2024.
About KORU Medical Systems
KORU Medical develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System (the “Freedom System”) currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Novel Therapies business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit www.korumedical.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241106560995/en/
Investor Contact:
Louisa Smith
investor@korumedical.com
Source: KORU Medical Systems
FAQ
When will KORU Medical Systems participate in the Craig-Hallum Alpha Select Conference?
What is the focus of KORU Medical Systems?
What is the stock symbol for KORU Medical Systems?
Which investor conferences will KORU Medical Systems attend in November 2024?
What is the date for the Canaccord MedTech, Diagnostics and Digital Health & Services Forum?
